Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HST003 for Knee Cartilage Defects
NCT05082831Phase 1Terminated
- Sponsor
- Histogen Inc.
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- ECM (Extracellular matrix)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of HST 003 in Cartilage defects and articular cartilage disorder of the knee (2 arms), sponsored by Histogen Inc. Primary endpoints: Knee Injury and Osteoarthritis Outcome Score at Day 168, International Knee Documentation Committee Questionnaire at Day 168 and 2 more. Started Nov 2021; status: terminated.
02
Drugs
HST 003
03
Conditions
Cartilage defectsarticular cartilage disorder of the knee
Beyond the preview
Go deeper on NCT05082831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082831.